Simon Lord

4.0k total citations · 3 hit papers
74 papers, 2.3k citations indexed

About

Simon Lord is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Simon Lord has authored 74 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 29 papers in Pulmonary and Respiratory Medicine and 27 papers in Molecular Biology. Recurrent topics in Simon Lord's work include Cancer, Hypoxia, and Metabolism (13 papers), HER2/EGFR in Cancer Research (10 papers) and Advanced Breast Cancer Therapies (8 papers). Simon Lord is often cited by papers focused on Cancer, Hypoxia, and Metabolism (13 papers), HER2/EGFR in Cancer Research (10 papers) and Advanced Breast Cancer Therapies (8 papers). Simon Lord collaborates with scholars based in United Kingdom, United States and Spain. Simon Lord's co-authors include Adrian L. Harris, Francesca M. Buffa, Elena Favaro, Ashvina Segaran, John Greene, Simon Wigfield, Fredrik Karpe, Zuo‐Feng Zhang, Caroline A. Lewis and Ji‐Liang Li and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Simon Lord

70 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fatty Acid Uptake and Lipid Storage Induced by HIF-1α Contribute to Cell Growth and Survival after Hypoxia-Reoxygenation

2014 525 citations Simon Lord, Simon Wigfield et al. profile →
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

2019 400 citations Fiona Thistlethwaite, Simon Lord et al. profile →
Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?

2023 82 citations Simon Lord, Adrian L. Harris British Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Simon Lord United Kingdom	19	976	920	906	546	422	74	2.3k
H. Charles Manning United States	18	544 0.6×	623 0.7×	769 0.8×	336 0.6×	240 0.6×	35	1.7k
Sung Gwe Ahn South Korea	24	868 0.9×	641 0.7×	714 0.8×	266 0.5×	328 0.8×	166	2.2k
Iain D. Miller United Kingdom	21	1.1k 1.1×	1.4k 1.5×	687 0.8×	821 1.5×	315 0.7×	36	3.1k
Cordula Petersen Germany	26	870 0.9×	493 0.5×	1.0k 1.1×	212 0.4×	435 1.0×	60	2.0k
Peng Yuan China	27	951 1.0×	735 0.8×	806 0.9×	226 0.4×	392 0.9×	148	2.1k
Huiqin Chen United States	21	1.0k 1.0×	726 0.8×	1.1k 1.2×	170 0.3×	543 1.3×	62	2.2k
Mark Dunphy United States	21	321 0.3×	412 0.4×	503 0.6×	782 1.4×	576 1.4×	55	1.8k
Mohammed A. Aleskandarany United Kingdom	36	1.6k 1.7×	1.5k 1.6×	1.7k 1.8×	222 0.4×	510 1.2×	81	3.4k
Andrew R. Reynolds United Kingdom	31	1.2k 1.2×	1.2k 1.3×	2.8k 3.1×	316 0.6×	641 1.5×	36	4.2k
Bassam Abdulkarim Canada	32	1.2k 1.2×	1.2k 1.3×	1.3k 1.4×	778 1.4×	878 2.1×	98	3.7k

Countries citing papers authored by Simon Lord

Since Specialization

Citations

This map shows the geographic impact of Simon Lord's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Lord with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Lord more than expected).

Fields of papers citing papers by Simon Lord

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Lord. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Lord. The network helps show where Simon Lord may publish in the future.

Co-authorship network of co-authors of Simon Lord

This figure shows the co-authorship network connecting the top 25 collaborators of Simon Lord. A scholar is included among the top collaborators of Simon Lord based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon Lord. Simon Lord is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cortés, Javier, Elena Garralda, Simon Lord, et al.. (2025). A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors. Clinical Cancer Research. 31(23). 4953–4963.

Kazmi, Farasat, Nipun Shrestha, Tiaotiao Liu, et al.. (2025). Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer. Cochrane Database of Systematic Reviews. 2025(3). CD014872–CD014872. 1 indexed citations

Schmid, Peter, Hao‐Chien Wang, Y.H. Park, et al.. (2025). 555MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment (tx) for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Final results from the phase Ib/II BEGONIA study. Annals of Oncology. 36. S413–S414. 1 indexed citations

Barberis, Alessandro, D. R. Hudson, David A. Harris, et al.. (2025). Defining hypoxia in cancer: A landmark evaluation of hypoxia gene expression signatures. Cell Genomics. 5(2). 100764–100764. 1 indexed citations

Dulloo, Sean, Simon Lord, Dean A. Fennell, et al.. (2024). Phase 2 study to evaluate the novel mitochondrial PRX3 inhibitor, RSO-021, as an intrapleural monotherapy and in combination with IV paclitaxel in patients with malignant pleural effusion due to mesothelioma or another advanced solid tumor.. Journal of Clinical Oncology. 42(16_suppl). TPS8124–TPS8124. 2 indexed citations

Lord, Simon, et al.. (2024). Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer. British Journal of Cancer. 131(11). 1724–1736. 7 indexed citations

Shaw, Rachel, Linda M. Collins, Pan Pantziarka, et al.. (2024). Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol. Trials. 25(1). 103–103. 5 indexed citations

Fennell, Dean A., Sean Dulloo, Simon Lord, et al.. (2024). First-in-human phase I clinical trial of RSO-021, a first-in class covalent inhibitor of mitochondrial peroxiredoxin 3 (PRX3), in patients with malignant pleural effusion due to mesothelioma and other advanced solid tumors (MITOPE).. Journal of Clinical Oncology. 42(16_suppl). 3019–3019. 5 indexed citations

Clift, Ash Kieran, Gary S. Collins, Simon Lord, et al.. (2023). Predicting 10-year breast cancer mortality risk in the general female population in England: a model development and validation study. The Lancet Digital Health. 5(9). e571–e581. 11 indexed citations

10.

Clift, Ash Kieran, David Dodwell, Simon Lord, et al.. (2023). Development and internal-external validation of statistical and machine learning models for breast cancer prognostication: cohort study. BMJ. 381. e073800–e073800. 46 indexed citations

11.

Macaulay, Valentine M., Simon Lord, Syed A. Hussain, et al.. (2023). A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer. British Journal of Cancer. 129(6). 965–973. 3 indexed citations

12.

Lord, Simon & Adrian L. Harris. (2023). Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?. British Journal of Cancer. 128(6). 958–966. 82 indexed citations breakdown →

13.

Bono, Johann S. de, Simon Lord, Christina Yap, et al.. (2023). 687P A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours. Annals of Oncology. 34. S479–S480. 1 indexed citations

14.

Cheng, Vinton W.T., Nick de Pennington, Rasheed Zakaria, et al.. (2022). VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface. Clinical Cancer Research. 28(11). 2385–2396. 16 indexed citations

15.

Clift, Ashley Kieran, Julia Hippisley–Cox, David Dodwell, et al.. (2022). Development and validation of clinical prediction models for breast cancer incidence and mortality: a protocol for a dual cohort study. BMJ Open. 12(3). e050828–e050828. 8 indexed citations

16.

Clift, Ash Kieran, David Dodwell, Simon Lord, et al.. (2021). The current status of risk-stratified breast screening. British Journal of Cancer. 126(4). 533–550. 67 indexed citations

17.

Harris, Benjamin, Ping Zhang, Lingyun Xiong, et al.. (2020). Heritable genetic variants in key cancer genes link cancer risk with anthropometric traits. Journal of Medical Genetics. 58(6). 392–399. 8 indexed citations

18.

Morotti, Matteo, Esther Bridges, Alessandro Valli, et al.. (2019). Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer. Proceedings of the National Academy of Sciences. 116(25). 12452–12461. 105 indexed citations

19.

Telli, Melinda L., Simon Lord, Emma Dean, et al.. (2017). Initial results of a phase 1 dose expansion cohort of M6620 (formerly VX-970), an ATR inhibitor, in combination with cisplatin in patients with advanced triple-negative breast cancer NCT02157792). Annals of Oncology. 28. v76–v76. 3 indexed citations

20.

Coupe, Nicholas, Avinash Gupta, & Simon Lord. (2015). Early phase cancer clinical trials: design, ethics and future directions. British Journal of Hospital Medicine. 76(7). 409–413. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact